128 related articles for article (PubMed ID: 18303270)
1. Leukopoiesis is not affected after intravenous treatment with the novel antineoplastic agent taurolidine. Results of an experimental study in rats.
Braumann C; Menenakos C; Atanassov V; Pfirrmann RW; Guenther N; Jacobi CA
Eur Surg Res; 2008; 40(4):341-6. PubMed ID: 18303270
[TBL] [Abstract][Full Text] [Related]
2. Wound healing is not impaired in rats undergoing perioperative treatment with the antineoplastic agent taurolidine.
Braumann C; Guenther N; Pohlenz J; Pfirrmann RW; Menenakos C
Eur Surg Res; 2009; 42(2):91-6. PubMed ID: 19088475
[TBL] [Abstract][Full Text] [Related]
3. Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats.
Braumann C; Schoenbeck M; Menenakos C; Kilian M; Jacobi CA
Clin Exp Metastasis; 2005; 22(1):77-83. PubMed ID: 16132581
[TBL] [Abstract][Full Text] [Related]
4. Taurolidine in the prevention and therapy of lung metastases.
Hoksch B; Rufer B; Gazdhar A; Bilici M; Beshay M; Gugger M; Schmid RA
Eur J Cardiothorac Surg; 2009 Dec; 36(6):1058-63. PubMed ID: 19850492
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer.
Darnowski JW; Goulette FA; Cousens LP; Chatterjee D; Calabresi P
Cancer Chemother Pharmacol; 2004 Sep; 54(3):249-58. PubMed ID: 15173956
[TBL] [Abstract][Full Text] [Related]
6. High doses of taurolidine inhibit advanced intraperitoneal tumor growth in rats.
Braumann C; Stuhldreier B; Bobrich E; Menenakos C; Rogalla S; Jacobi CA
J Surg Res; 2005 Nov; 129(1):129-35. PubMed ID: 15916768
[TBL] [Abstract][Full Text] [Related]
7. The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model.
Braumann C; Jacobi CA; Rogalla S; Menenakos C; Fuehrer K; Trefzer U; Hofmann M
J Surg Res; 2007 Dec; 143(2):372-8. PubMed ID: 17612567
[TBL] [Abstract][Full Text] [Related]
8. Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy.
Braumann C; Ordemann J; Kilian M; Wenger FA; Jacobi CA
Clin Exp Metastasis; 2003; 20(5):387-94. PubMed ID: 14524527
[TBL] [Abstract][Full Text] [Related]
9. Influence of intraperitoneal application of taurolidine/heparin on expression of adhesion molecules and colon cancer in rats undergoing laparoscopy.
Bobrich E; Braumann C; Opitz I; Menenakos C; Kristiansen G; Jacobi CA
J Surg Res; 2007 Jan; 137(1):75-82. PubMed ID: 17109891
[TBL] [Abstract][Full Text] [Related]
10. Instillation of taurolidine/heparin after laparotomy reduces intraperitoneal tumour growth in a colon cancer rat model.
Opitz I; Van der Veen H; Witte N; Braumann C; Mueller JM; Jacobi CA
Eur Surg Res; 2007; 39(3):129-35. PubMed ID: 17337889
[TBL] [Abstract][Full Text] [Related]
11. Impact of taurolidine on the growth of CC531 coloncarcinoma cells in vitro and in a laparoscopic animal model in rats.
Nestler G; Schulz HU; Schubert D; Krüger S; Lippert H; Pross M
Surg Endosc; 2005 Feb; 19(2):280-4. PubMed ID: 15870965
[TBL] [Abstract][Full Text] [Related]
12. Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo.
Abramjuk C; Bueschges M; Schnorr J; Jung K; Staack A; Lein M
Oncol Rep; 2009 Aug; 22(2):409-14. PubMed ID: 19578784
[TBL] [Abstract][Full Text] [Related]
13. Taurolidine-Fibrin-Sealant-Matrix using spray application for local treatment of brain tumors.
Stendel R; Scheurer L; Schlatterer K; Gminski R; Möhler H
Anticancer Res; 2004; 24(2B):631-8. PubMed ID: 15161005
[TBL] [Abstract][Full Text] [Related]
14. RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer - the S.U.R.G.U.V.A.N.T. trial.
Redmond HP; Neary PM; Jinih M; O'Connell E; Foley N; Pfirrmann RW; Wang JH; O'Leary DP
BMC Cancer; 2018 Aug; 18(1):794. PubMed ID: 30081854
[TBL] [Abstract][Full Text] [Related]
15. Intra-abdominal use of taurolidine or heparin as alternative products to an antiadhesive barrier (Seprafilm) in adhesion prevention: an experimental study on mice.
Bahadir I; Oncel M; Kement M; Sahip Y
Dis Colon Rectum; 2007 Dec; 50(12):2209-14. PubMed ID: 17902020
[TBL] [Abstract][Full Text] [Related]
16. The antitumor effect of a novel nitrosourea, tauromustine, at intravenous administration in rat. Cure of hepatomas.
Roos G; el Hag IA; Christensson PI; Stenram U
Anticancer Res; 1991; 11(5):1763-6. PubMed ID: 1837442
[TBL] [Abstract][Full Text] [Related]
17. Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case.
Braumann C; Winkler G; Rogalla P; Menenakos C; Jacobi CA
World J Surg Oncol; 2006 Jun; 4():34. PubMed ID: 16796759
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of normal saline and taurolidine on intra-abdominal adhesion formation and peritoneal fibrinolysis.
Tarhan OR; Barut I; Sezik M
J Surg Res; 2008 Jan; 144(1):151-7. PubMed ID: 17981298
[TBL] [Abstract][Full Text] [Related]
19. Effects of topical application of taurolidine on second intention healing of experimentally induced wounds in rats.
Simpson JM; Séguin B; Gitelman AI
Am J Vet Res; 2008 Sep; 69(9):1210-6. PubMed ID: 18764696
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of taurolidine metabolites in healthy volunteers.
Gong L; Greenberg HE; Perhach JL; Waldman SA; Kraft WK
J Clin Pharmacol; 2007 Jun; 47(6):697-703. PubMed ID: 17395893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
